Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C⁺ NK cells to target myeloid leukemia.

ABSTRACT: Natural killer (NK) cells mediate the cytolysis of transformed cells and are currently used as an adoptive cellular therapy to treat cancer. Infection with human cytomegalovirus has been shown to expand a subset of "adaptive" NK cells expressing the activation receptor NKG2C that have preferred functional attributes distinct from conventional NK cells. Because NKG2C delivers a strong activating signal to NK cells, we hypothesized that NKG2C could specifically trigger NK-cell-mediated antitumor responses. To elicit a tumor-directed response from NKG2C⁺ NK cells, we created an anti-NKG2C/IL-15/anti-CD33 killer engager called NKG2C-KE that directs NKG2C⁺ cells to target CD33⁺ cells and tumor-associated antigen expressed by acute myelogenous leukemia cells. The

SUBMITTER: Chiu E 

PROVIDER: S-EPMC8636174 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature